Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
The U.S. Food and Drug Administration (FDA) issued a drug safety communication on October 10, announcing that it is requiring Carvykti following reports of immune effector cell-associated enterocolitis (IEC-EC).IncreaseNew Black Box Warning. The FDA warns that the side effects of IEC-EC may cause severe or long-term diarrhea, abdominal pain, and weight loss, requiring intravenous treatment.
The FDA has completed its review of clinical trial data and post-marketing adverse event reports, approving updates to the prescribing information and medication guide, including black box warnings, warnings and precautions, and adverse reactions (post-marketing experience section), to incorporate the risk of IEC-EC.FDA Accepts Clinical Trial and Post-Market DataCarvyktiTreatment of Patients with IEC-EC Report. Patients with IEC-EC experience severe or chronic diarrhea, abdominal pain, and weight loss, requiring total parenteral nutrition. IEC-EC occursCarvyktiWeeks to months after infusion. In addition to supportive care and total parenteral nutrition, various immunosuppressive therapies including corticosteroids are required. IEC-EC is associated with fatal outcomes such as intestinal perforation and sepsis.FDA also approved the update of the clinical research section of the drug label., included in the CARTITUDE-4 trial, a randomized, open-label, multicenter controlled study of adult patients with relapsed and lenalidomide-refractory multiple myeloma who had previously received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. The estimated median follow-up time was 33.6 months, and a pre-specified second interim analysis showed,CarvyktiThe improvement in OS with the regimen compared to standard treatment is statistically significant.Carvykti was first approved in February 2022 and received expanded approval in April 2024 for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. Due to adverse side effects, this class of CAR-T drugs came under stricter scrutiny almost immediately. In January 2024, the FDA required several CAR-T drugs, including Carvykti, to add a black box warning indicating that their side effects may increase the risk of T-cell malignancies, potentially leading to hospitalization or even death. Previously, FDA researchers identified 22 cases of secondary cancers linked to CAR-T side effects.Reference: FDA official website
Mastering CAR-T Therapy, Stem Cell Therapy, and Gene
Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
